For the quarter ending 2025-09-30, TYRA had -$30,015K decrease in cash & cash equivalents over the period. -$71,602K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -86,113 | - |
| Depreciation | 414 | - |
| Stock-based compensation | 20,379 | - |
| Accretion of marketable securities, net | -1,993 | - |
| Prepaid expenses and other assets | 5,484 | - |
| Accounts payable, accrued expenses and other liabilities | 1,213 | - |
| Right-of-use assets and lease liabilities, net | 66 | - |
| Net cash used in operating activities | -71,518 | - |
| Purchases of marketable securities | 92,148 | - |
| Maturities of marketable securities | 130,318 | - |
| Purchases of property and equipment | 84 | - |
| Net cash provided by (used in) investing activities | 38,086 | - |
| Proceeds from issuances of common stock under benefit plans | 3,417 | - |
| Proceeds from issuance of common stock and pre-funded warrants from private placement | 0 | - |
| Payments of issuance costs for common stock and pre-funded warrants from private placement | 0 | - |
| Net cash provided by financing activities | 3,417 | - |
| Restricted cash | - | 1,000 |
| Net cash increase (decrease) for the period | -30,015 | - |
| Cash and cash equivalents | - | 98,490 |
| Cash and cash equivalents at beginning of period | 92,966 | - |
| Cash and cash equivalents at end of period | 62,951 | 99,490 |
Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA)